| 注册
首页|期刊导航|中国药物评价|抗体偶联药物生产关键环节GMP检查研究

抗体偶联药物生产关键环节GMP检查研究

马岩松 董方 康鹰 颜若曦

中国药物评价2025,Vol.42Issue(4):241-250,10.
中国药物评价2025,Vol.42Issue(4):241-250,10.

抗体偶联药物生产关键环节GMP检查研究

Research on GMP Inspection of Key Processes in the Production of Antibody-Drug-Conjugates

马岩松 1董方 1康鹰 1颜若曦1

作者信息

  • 1. 国家药品监督管理局食品药品审核查验中心,北京 100076
  • 折叠

摘要

Abstract

This paper explores the key processes in the production of Antibody-Drug Conjugates(ADCs)and related research on GMP(Good Manufacturing Practice)inspections.It outlines the basic structure,mechanism of action,and production process flow of ADCs,including key steps such as the production of antibody intermediates,payload production,Linker-payload synthesis,ADC conjugation pro-duction,ADC purification,and formulation production.The article analyzes the current development status,market prospects,as well as the complexities and challenges in the production process of ADC drugs.It summarizes the GMP-related regulatory requirements for ADC drug production.On this basis,it elaborates in detail on the GMP inspection points for each key production link of ADC drugs,as well as the particularities of GMP requirements for ADC production.In view of the special GMP considerations in the production of ADC drugs,the article proposes technical difficulties,challenges,strategies,and suggestions for GMP inspections,aiming to provide references for quality management of ADC drug production enterprises and GMP inspections by regulatory agencies.

关键词

抗体偶联药物/GMP检查/生产工艺/质量管理/监管机构

Key words

Antibody-drug conjugates/GMP inspection/Production process/Quality management/Regulatory agencies

分类

医药卫生

引用本文复制引用

马岩松,董方,康鹰,颜若曦..抗体偶联药物生产关键环节GMP检查研究[J].中国药物评价,2025,42(4):241-250,10.

中国药物评价

2095-3593

访问量0
|
下载量0
段落导航相关论文